Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial

Tina J. Hieken, Garth D. Nelson, Thomas J. Flotte, Eric P. Grewal, Jun Chen, Robert R. McWilliams, Lisa A. Kottschade, Lu Yang, Evidio Domingo-Musibay, Roxana S. Dronca, Yiyi Yan, Svetomir N. Markovic, Anastasios Dimou, Heather N. Montane, Courtney L. Erskine, Mara A. Piltin, Daniel L. Price, Samir S. Khariwala, Jane Hui, Carrie A. StrandSusan M. Harrington, Vera J. Suman, Haidong Dong, Matthew S. Block

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds

Physics & Astronomy